Skip to main content
Macrogen, Inc. logo

Macrogen, Inc. — Investor Relations & Filings

Ticker · 038290 ISIN · KR7038290003 KO Professional, scientific and technical activities
Open in API
Filings indexed 352 across all filing types
Latest filing 2020-09-23 Legal Proceedings Report
Country KR South Korea
Listing KO 038290

About Macrogen, Inc.

https://www.macrogen.com/en/main

Macrogen, Inc. is a biotechnology company specializing in precision medicine and genomic analysis. It provides a comprehensive suite of services, including Next-Generation Sequencing (NGS), Sanger sequencing, and spatial transcriptome analysis, to a global client base. The company's core activities are focused on three key areas: Research and Data Analysis, offering fast and accurate genomic services to the scientific community; Clinical Diagnostics, advancing disease prediction through the integration of genomic and medical big data; and Personal Healthcare, providing genetic tests for wellness, nutrition, and disease risk assessment. By combining its extensive genomic expertise with big data and AI, Macrogen aims to deliver hyper-personalized healthcare solutions and innovate in the field of future medicine.

Recent filings

Filing Released Lang Actions
소송등의제기ㆍ신청(경영권분쟁소송)(주주명부 열람 및 등사 가처분)
Legal Proceedings Report Classification · 100% confidence The document is a formal disclosure regarding a legal proceeding ('소송 등의 제기ㆍ신청') specifically involving a management dispute ('경영권 분쟁 소송') and a request for shareholder list inspection ('주주명부 열람 및 등사 가처분'). This falls under the category of legal proceedings and regulatory disclosures regarding litigation.
2020-09-23 Korean
투자판단관련주요경영사항(유방암, 난소암 환자의 분자유전학적 분별진단을 위한 체외분자진단제품(Axen BRCA Library Kit)의 의료기기 제조허가 반려)
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure filed by Macrogen regarding the rejection of a medical device manufacturing permit by the Ministry of Food and Drug Safety (MFDS). It details a specific material event (the rejection of a product application) that impacts investment decisions. Since it does not fit into specific categories like M&A, dividends, or share transactions, and is a formal regulatory announcement of a business event, it is classified as a Regulatory Filing (RNS).
2020-09-14 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is an announcement regarding an upcoming Investor Relations (IR) meeting/presentation scheduled for September 1, 2020. It provides details such as the date, location, purpose, and registration instructions for investors. Since this is an announcement of an event rather than the presentation materials themselves, and it does not fit into other specific categories like 'Investor Presentation' (which would contain the actual slides/data), it is classified as a Regulatory Filing (RNS) as it serves as a formal notice of a corporate event.
2020-08-25 Korean
반기보고서 (2020.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for the company Macrogen, covering the period from January 1, 2020, to June 30, 2020. It contains detailed financial information, business descriptions, and corporate governance data, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2020
2020-08-14 Korean
[기재정정]유상증자결정(종속회사의주요경영사항)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from a Korean company (Macrogen) regarding a 'Capital Increase Decision' (유상증자결정) for its subsidiary, Psomagen. It details the issuance of new shares, the purpose of the capital raise, and the final offering price. This falls under the category of capital structure changes and financing activities, specifically share issuance.
2020-06-25 Korean
투자판단관련주요경영사항(유방암, 난소암 환자의 분자유전학적 분별진단을 위한 체외분자진단제품(Axen BRCA Library Kit)의 의료기기 제조허가 신청)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from the Korean stock exchange (KIND) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It details the application for medical device manufacturing approval for a specific product (Axen BRCA Library Kit) to the Ministry of Food and Drug Safety. Since this is a specific regulatory disclosure of a material business event that does not fit into categories like financial reports, dividends, or board changes, it is classified as a Regulatory Filing (RNS).
2020-06-04 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.